Triangle Pharmaceuticals Applies For FDA Marketing Approval of Antiretroviral Drug Coviracil
Durham, N.C.-based Triangle Pharmaceuticals on Wednesday announced that it had applied for FDA marketing approval for the antiretroviral drug Coviracil, Reuters reports. "We believe that once approved, the potency, once-daily dosing and pharmacokinetic profile of Coviracil will offer patients and physicians an important new tool in the management of HIV disease," Daniel Welch, chair and CEO of Triangle, said. Welch added that the company intends to apply for European marketing approval for the nucleoside reverse transcriptase inhibitor next (Reuters, 9/4). The drug company last month announced that it was looking for a "successful AIDS franchise" to join it in marketing Coviracil (Kaiser Daily HIV/AIDS Report, 8/15).This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.